Last reviewed · How we verify
Cyclophosphamide + Bortezomib + Dexamethasone regimen
Cyclophosphamide + Bortezomib + Dexamethasone regimen is a Combination chemotherapy regimen (alkylating agent + proteasome inhibitor + corticosteroid) Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Multiple myeloma (induction therapy), Light chain deposition disease, Waldenström macroglobulinemia.
This three-drug combination kills cancer cells through DNA damage (cyclophosphamide), proteasome inhibition (bortezomib), and glucocorticoid immunosuppression (dexamethasone).
This three-drug combination kills cancer cells through DNA damage (cyclophosphamide), proteasome inhibition (bortezomib), and glucocorticoid immunosuppression (dexamethasone). Used for Multiple myeloma (induction therapy), Light chain deposition disease, Waldenström macroglobulinemia.
At a glance
| Generic name | Cyclophosphamide + Bortezomib + Dexamethasone regimen |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Combination chemotherapy regimen (alkylating agent + proteasome inhibitor + corticosteroid) |
| Target | DNA (cyclophosphamide); 26S proteasome (bortezomib); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide is an alkylating agent that cross-links DNA and triggers cell death. Bortezomib inhibits the 26S proteasome, preventing degradation of pro-apoptotic proteins and causing accumulation of misfolded proteins in cancer cells. Dexamethasone is a corticosteroid that enhances the anti-tumor effect and reduces inflammation. Together, these agents target multiple pathways to overcome drug resistance in hematologic malignancies.
Approved indications
- Multiple myeloma (induction therapy)
- Light chain deposition disease
- Waldenström macroglobulinemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Peripheral neuropathy
- Infection
- Nausea and vomiting
- Fatigue
- Hyperglycemia
Key clinical trials
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) (PHASE3)
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (PHASE3)
- A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (PHASE2)
- A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel (PHASE2)
- A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclophosphamide + Bortezomib + Dexamethasone regimen CI brief — competitive landscape report
- Cyclophosphamide + Bortezomib + Dexamethasone regimen updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Cyclophosphamide + Bortezomib + Dexamethasone regimen
What is Cyclophosphamide + Bortezomib + Dexamethasone regimen?
How does Cyclophosphamide + Bortezomib + Dexamethasone regimen work?
What is Cyclophosphamide + Bortezomib + Dexamethasone regimen used for?
Who makes Cyclophosphamide + Bortezomib + Dexamethasone regimen?
What drug class is Cyclophosphamide + Bortezomib + Dexamethasone regimen in?
What development phase is Cyclophosphamide + Bortezomib + Dexamethasone regimen in?
What are the side effects of Cyclophosphamide + Bortezomib + Dexamethasone regimen?
What does Cyclophosphamide + Bortezomib + Dexamethasone regimen target?
Related
- Drug class: All Combination chemotherapy regimen (alkylating agent + proteasome inhibitor + corticosteroid) drugs
- Target: All drugs targeting DNA (cyclophosphamide); 26S proteasome (bortezomib); glucocorticoid receptor (dexamethasone)
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Multiple myeloma (induction therapy)
- Indication: Drugs for Light chain deposition disease
- Indication: Drugs for Waldenström macroglobulinemia
- Compare: Cyclophosphamide + Bortezomib + Dexamethasone regimen vs similar drugs
- Pricing: Cyclophosphamide + Bortezomib + Dexamethasone regimen cost, discount & access